• Maintenance infusions should be reduced by one-third in patients with moderate renal impairment and by two-thirds in patients with severe renal impairment. (medscape.com)
  • Once renal impairment has been identified (be it AKI or chronic kidney disease) and creatinine clearance (Cr Cl) estimated, the need for dose alteration of renally eliminated drugs must be determined. (aneskey.com)
  • In addition, coadministration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and coadministration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. (guidelinecentral.com)
  • Severe renal impairment. (azurewebsites.net)
  • Below are the warnings and precautions to be taken when using Generic Glucophage (Metformin HCl Tablets): The risk of lactic acidosis caused by Metformin increases with the degree of renal dysfunction, impairment of creatinine clearance and the patient's age. (strapcart.com)
  • Renal Failure, Severe Renal Or Hepatic Impairment, Acute Conditions Which May Affect Renal Function E.G. Dehydration, Severe Infection Or Shock. (strapcart.com)
  • If you have renal impairment. (cheapmedicineshop.com)
  • Renal impairment: The combination can be used in patients with renal impairment. (shombhob.com)
  • In patients with hepatic impairment (hepatitis or cirrhosis) or renal dysfunction (creatinine clearance less than 40 mL/min) as in other patients, the initial daily dose should be 5 mg. (com.bd)
  • concurrent use contraindicated in patients with renal or hepatic impairment. (drugguide.com)
  • Disopyramide phosphate is a Type 1 antiarrhythmic drug (i.e., similar to procainamide and quinidine). (nih.gov)
  • The anticholinergic effect of drugs such as tri- and tetracyclic antidepressants, antihistamines, quinidine, amantadine, antipsychotics (e.g. butyrophenones, phenothiazines), disopyramide and other anticholinergics (e.g. tiotropium, ipratropium, atropine-like compounds) may be intensified by Buscopan. (janusinfo.se)
  • The anticholinergic effect of drugs such as tricyclic antidepressants, antihistamines, quinidine, amantadine, disopyramide and other anticholinergics (tiotropium, ipratropium) may be intensified by Hyoscine-N-butylbromide. (wellingtonicu.com)
  • Adenosine is a potent vasodilator in most vascular beds, except in renal afferent arterioles and hepatic veins where it produces vasoconstriction. (globalrph.com)
  • patients with hepatic cirrhosis together with impaired renal function. (medthority.com)
  • Dosage is stated for adults with normal renal and hepatic function unless otherwise specified. (wellingtonicu.com)
  • Other considerations prior to medication administration include documentation of adequate renal function with Cr and BUN levels, documentation of adequate hepatic function with ALT and TBil levels, and documentation of adequate hematological and immune function with platelet and WBC count. (unboundmedicine.com)
  • The clearance of Bisoprolol is balanced between renal elimination of the unchanged molecule (-50%) and hepatic metabolism (-50%) to metabolites which are also renally excreted. (com.bd)
  • In six patients with impaired renal function (creatinine clearance less than 40 mL/min), disopyramide half-life values were 8 to 18 hours. (nih.gov)
  • Azissel uses with careful with impaired renal function. (sdrugs.com)
  • Frequent checks of the serum potassium level are necessary in patients with impaired renal function and a creatinine clearance below 60ml/min per 1.73m 2 body surface area as well as in cases where Co-amilofruse is taken in combination with certain other drugs which may lead to an increase in potassium levels. (medthority.com)
  • Although dual-chamber pacing has been used with caution in diabetes mellitus, hypothyroidism, nephrotic syndrome, hus miscellaneous agents allopurinol ain cimetidine ain, decreased creatinine secretion disopyramide obstructive uropathy from renal insufficiency, hypokalemia requiring simulta-neous potassium supplementation, and nutrition. (elastizell.com)
  • It must be remembered that serum creatinine concentration is not a reliable measure of renal function in older people because of age-related reductions in muscle mass. (aneskey.com)
  • Intravenous disopyramide phosphate may cause cardiac depression with an approximate mean 10% reduction of cardiac output, which is more pronounced in patients with cardiac dysfunction. (nih.gov)
  • Lactic acidosis may also occur in association with a number of pathophysiologic conditions, including diabetes mellitus, and whenever there is significant tissue hypoperfusion and hypoxemia or significant renal dysfunction. (pdr.net)
  • however, the usual dose for disopyramide phosphate is 150 mg every 6 hours compared to 0.4 to 0.6 mg for atropine (see WARNINGS and ADVERSE REACTIONS for anticholinergic side effects). (nih.gov)
  • ICER estimated the annual cost for competing therapies as $8,559 for disopyramide plus dose initiation hospitalization, $122,750 for myectomy and $55,706 for septal ablation. (prescriberight.com)
  • In animal studies, disopyramide phosphate decreases the rate of diastolic depolarization (phase 4) in cells with augmented automaticity, decreases the upstroke velocity (phase 0) and increases the action potential duration of normal cardiac cells, decreases the disparity in refractoriness between infarcted and adjacent normally perfused myocardium, and has no effect on alpha- or beta-adrenergic receptors. (nih.gov)
  • After the oral administration of 200 mg of disopyramide to 10 cardiac patients with borderline to moderate heart failure, the time to peak serum concentration of 2.3 ± 1.5 hours (mean ± SD) was increased, and the mean peak serum concentration of 4.8 ± 1.6 mcg/mL was higher than in healthy volunteers. (nih.gov)
  • In a 38 patient, Phase II, open-label trial, treatment with camrelizumab plus famitinib resulted in an overall response rate of 60.5% in Chinese patients with advanced or metastatic renal cell carcinoma. (prescriberight.com)
  • Pazopanib is used to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the cells of the kidneys) in adults. (medlineplus.gov)
  • Metformin Effects May Be Increased By ACE Inhibitors, Disopyramide, MAOIs. (strapcart.com)
  • Bisoprolol fumarate should be used with care when myocardial depressants or inhibitors of A-V conduction, such as certain calcium antagonists (particularly of the phenyl alkylamine (verapamil) and benzothiazepine (diltiazem) classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (com.bd)
  • Unlike propranolol or metoprolol, but like nadolol, atenolol tablets undergo little or no metabolism by the liver, and the absorbed portion is eliminated primarily by renal excretion. (nih.gov)
  • While the use of drugs lithium, indapamide increases the concentration of lithium ions in the plasma (by reducing its renal excretion). (pharmru.com)
  • The maintenance infusion of up to 0.5 mg/min can be cautiously continued for 2 to 3 weeks regardless of the patient's age, renal function, or Left-ventricular function. (globalrph.com)
  • One of the most important age-related pharmacokinetic changes is the predictable decline in renal function. (aneskey.com)
  • Adjust dosage carefully according to individual requirements and response, age, renal function, and the general condition and cardiovascular status of the patient. (drugs.com)
  • Treatment with Metformin should be temporarily discontinued 2 days prior to any intravascular radiocontrast study and not restarted until renal function has normalised. (strapcart.com)
  • Renal function should be assessed before and during treatment with Tybost, and patients who experience changes in renal function should be monitored closely. (rxwiki.com)
  • Disopyramide phosphate is an antiarrhythmic drug available for oral administration in capsules containing 100 mg or 150 mg of disopyramide base, present as the phosphate. (nih.gov)
  • With intravenous disopyramide phosphate, either increases in systolic/diastolic or decreases in systolic blood pressure have been reported, depending on the infusion rate and the patient population. (nih.gov)
  • Angiotensin converting enzyme while the use of indapamide increased risk of developing orthostatic hypotension and / or acute renal failure (especially in the presence of renal artery stenosis). (pharmru.com)
  • and renal failure and other edematous disorders. (druginteractionchecker.com)
  • During a median follow-up of 42 (IQR 21-98) months, one patient experienced advanced atrioventricular block requiring pacemaker implantation and one end-stage renal disease requiring dialysis. (bvsalud.org)
  • Disopyramide is used for preventing and restoring atrial and ventricular extrasystole and tachycardia in order to prevent atrial flutter and arrhythmia. (chemicalbook.com)
  • In man, disopyramide phosphate at therapeutic plasma levels shortens the sinus node recovery time, lengthens the effective refractory period of the atrium, and has a minimal effect on the effective refractory period of the AV node. (nih.gov)
  • Following oral administration of disopyramide phosphate, disopyramide phosphate is rapidly and almost completely absorbed, and peak plasma levels are usually attained within 2 hours. (nih.gov)
  • In addition, coadministration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and coadministration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. (nih.gov)
  • Hypersensitivity to enalapril and other ACE inhibitors, history of angioneurotic edema associated with treatment with ACE inhibitors, hereditary or idiopathic angioedema, simultaneous application of aliskiren and / or aliskirensoderzhaschimi drugs in patients with diabetes and / or moderate to severe renal impairment (glomerular filtration rate (GFR) of less than 60 ml / min / 1.73 m2), pregnancy, breast-feeding, age 18 years (efficacy and safety have not mouth ovleny). (pharmru.com)
  • Increased sensitivity to the drug, other sulfonamide derivatives or other ingredients, anuria, refractory hypokalemia, severe liver failure (including encephalopathy) and / or severe renal impairment (creatinine clearance less than 30 mL / min), pregnancy, breast feeding, age and 18 years (effectiveness and safety have been established). (pharmru.com)
  • If you are at high risk of the diarrhoea leading to severe illness, e.g. poorly controlled diabetes, renal impairment, heart failure, reduced CD4 HIV or other reduced immunity. (doctorfox.co.uk)
  • Chronic renal impairment associated with the development of TTP has been reported. (drugs.com)
  • severe hepatic failure in combination with renal impairment. (azurewebsites.net)
  • Patient with renal impairment concurrently taking atazanavir or ritonavir-containing regimens. (azurewebsites.net)
  • Hepatic and moderate to severe renal impairment. (azurewebsites.net)
  • In patients with hepatic impairment ( hepatitis or cirrhosis ) or renal dysfunction ( creatinine clearance less than 40 mL/min), the initial daily dose should be 2.5 mg and caution should be used in dose-titration. (wikidoc.org)
  • Norpace (disopyramide phosphate) is an antiarrhythmic drug available for oral administration in immediate-release and controlled-release capsules containing 100 mg or 150 mg of disopyramide base, present as the phosphate. (nih.gov)
  • Norpace CR (controlled-release) capsules are designed to afford a gradual and consistent release of disopyramide. (nih.gov)
  • Following oral administration of immediate-release Norpace, disopyramide phosphate is rapidly and almost completely absorbed, and peak plasma levels are usually attained within 2 hours. (nih.gov)
  • Furosemide Injection 250mg/25ml is for use in the management of oliguria due to acute or chronic renal insufficiency with a glomerular filtration rate below 20ml/minute. (tajgenerics.com)
  • In six patients with impaired renal function (creatinine clearance less than 40 mL/min), disopyramide half-life values were 8 to 18 hours. (nih.gov)
  • For patients with moderate renal insufficiency ( creatinine clearance greater than 40 mL/min) or hepatic insufficiency , the recommended dosage is 400 mg/day given in divided doses (100 mg every 6 hours). (wikidoc.org)
  • Impaired renal function with a creatinine clearance below 30ml/min per 1.73 m 2 body surface area (see section 4.4). (tajgenerics.com)
  • In selecting a LANOXIN dosing regimen, it is important to consider factors that affect digoxin blood levels (e.g., body weight, age, renal function, concomitant drugs) since toxic levels of digoxin are only slightly higher than therapeutic levels. (rxlist.com)
  • GI decontamination is sometimes warranted to decrease GI disopyramide absorption, because of its anticholinergic effects. (medscape.com)
  • however, the usual dose for disopyramide (as the phosphate) is 150 mg every 6 hours, compared to 0.4 to 0.6 mg for atropine (see WARNINGS and ADVERSE REACTIONS for anticholinergic side effects). (nih.gov)
  • In the event of increased anticholinergic side effects , plasma levels of disopyramide should be monitored and the dose of the drug adjusted accordingly. (wikidoc.org)
  • It is not necessary to adjust the dose in the elderly, unless there is also significant renal dysfunction or hepatic dysfunction . (wikidoc.org)
  • Kidney (renal) disease, since your doctor may need to check the dose of your other medicines (such as protease inhibitors). (antiinfectivemeds.com)
  • The usual adult dosage of disopyramide phosphate is 400 to 800 mg per day given in divided doses. (wikidoc.org)
  • If there is no response to this dosage within 48 hours, either disopyramide phosphate should then be discontinued or the physician should consider hospitalizing the patient for careful monitoring while subsequent disopyramide phosphate doses of 250 mg or 300 mg every 6 hours are given. (wikidoc.org)
  • A limited number of patients with severe refractory ventricular tachycardia have tolerated daily doses of disopyramide phosphate up to 1600 mg per day (400 mg every 6 hours), resulting in disopyramide plasma levels up to 9 mcg/mL. (wikidoc.org)
  • Dosages for children must be determined on the basis of the severity of the renal insufficiency and on the clinical response to initial doses. (tajgenerics.com)
  • In animal studies disopyramide decreases the rate of diastolic depolarization (phase 4) in cells with augmented automaticity, decreases the upstroke velocity (phase 0) and increases the action potential duration of normal cardiac cells, decreases the disparity in refractoriness between infarcted and adjacent normally perfused myocardium, and has no effect on alpha- or beta-adrenergic receptors. (nih.gov)
  • Intravenous disopyramide may cause cardiac depression with an approximate mean 10% reduction of cardiac output, which is more pronounced in patients with cardiac dysfunction. (nih.gov)
  • After the oral administration of 200 mg of disopyramide to 10 cardiac patients with borderline to moderate heart failure, the time to peak serum concentration of 2.3 ± 1.5 hours (mean ± SD) was increased, and the mean peak serum concentration of 4.8 ± 1.6 mcg/mL was higher than in healthy volunteers. (nih.gov)
  • The indications include cardiac, pulmonary, hepatic and renal oedema. (tajgenerics.com)
  • Considering the known proarrhythmic properties of Disopyramide Phosphate and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of Disopyramide Phosphate as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias. (wikidoc.org)
  • For patients with severe renal insufficiency (Ccr 40 mL/min or less), the recommended dosage regimen is 100 mg at intervals shown in the table below, with or without an initial loading dose of 150 mg. (wikidoc.org)
  • Disopyramide phosphate is freely soluble in water, and the free base (pKa 10.4) has an aqueous solubility of 1 mg/mL. (nih.gov)
  • Disopyramide phosphate is a racemic mixture of d - and l -isomers. (nih.gov)
  • Disopyramide phosphate capsules (equivalent to 100 mg Disopyramide Base) and Disopyramide phosphate capsules (equivalent to 150 mg Disopyramide Base) contain the following inactive ingredients: magnesium stearate, microcrystalline cellulose and sodium lauryl sulfate. (nih.gov)
  • The dosage of disopyramide phosphate must be individualized for each patient on the basis of response and tolerance. (wikidoc.org)
  • For patients in whom rapid control of ventricular arrhythmia is essential, an initial loading dose of 300 mg of disopyramide phosphate (200 mg for patients whose body weight is less than 110 pounds) is recommended, followed by the appropriate maintenance dosage. (wikidoc.org)
  • If there is no response or evidence of toxicity within 6 hours of the loading dose, 200 mg of disopyramide phosphate every 6 hours may be prescribed instead of the usual 150 mg. (wikidoc.org)
  • If you have low blood pressure, diabetes, renal or liver disease, a decreased heart rate. (pharmeasy.in)
  • Disopyramide is also known to cause hypoglycemia, through unclear mechanisms. (medscape.com)
  • 9. Population Pharmacokinetic-Toxicodynamic Modeling and Simulation of Cisplatin-Induced Acute Renal Injury in Rats: Effect of Dosing Rate on Nephrotoxicity. (nih.gov)
  • With intravenous disopyramide, either increases in systolic/diastolic or decreases in systolic blood pressure have been reported, depending on the infusion rate and the patient population. (nih.gov)
  • Maternal serum and breast milk were obtained to determine the concentration of disopyramide (DP) and its metabolite N-monodesalkyl disopyramide (NMD) from a woman requiring antidysrhythmic drug therapy. (nih.gov)
  • In man, disopyramide at therapeutic plasma levels shortens the sinus node recovery time, lengthens the effective refractory period of the atrium, and has a minimal effect on the effective refractory period of the AV node. (nih.gov)
  • The mean plasma half-life of disopyramide in healthy humans is 6.7 hours (range of 4 to 10 hours). (nih.gov)